Medical Transcription Billing (MTBC) Downgraded to Sell at ValuEngine
ValuEngine cut shares of Medical Transcription Billing (NASDAQ:MTBC) from a hold rating to a sell rating in a report released on Monday.
Several other analysts have also commented on MTBC. Zacks Investment Research raised Medical Transcription Billing from a hold rating to a buy rating and set a $1.50 price objective on the stock in a report on Wednesday, August 16th. Chardan Capital raised their price objective on Medical Transcription Billing from $2.25 to $2.75 and gave the company a buy rating in a report on Tuesday, November 14th.
Shares of Medical Transcription Billing (MTBC) traded down $0.02 on Monday, reaching $2.61. The company’s stock had a trading volume of 188,600 shares, compared to its average volume of 1,171,590. The company has a current ratio of 1.15, a quick ratio of 1.15 and a debt-to-equity ratio of 0.01. Medical Transcription Billing has a one year low of $0.29 and a one year high of $5.44.
TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/08/medical-transcription-billing-mtbc-downgraded-to-sell-at-valuengine.html.
About Medical Transcription Billing
Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related stocks with our FREE daily email newsletter.